Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022
18 Março 2022 - 9:00AM
Business Wire
Biocept, Inc. (Nasdaq: BIOC) announces that it will release
financial results for the three and 12 months ended December 31,
2021 and will file its Annual Report on Form 10-K with the
Securities and Exchange Commission (SEC) on Thursday, March 31,
2022. Management will not hold an investment community conference
call with the reporting of 2021 fourth quarter and full year
financial results.
Biocept plans to announce financial results for the three months
ended March 30, 2022 in mid-May 2022. Management plans to hold an
investment community conference call in conjunction with reporting
first quarter 2022 financial results in which it plans to unveil
the company’s rationalized business strategy including near-term
milestones.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept has developed the CNSide™
cerebrospinal fluid assay that detects cancer that has metastasized
to the central nervous system. Biocept’s patented Target Selector™
technology captures and quantitatively analyzes CSF tumor cells for
tumor-associated molecular markers, using technology first
developed for use in blood. Biocept also is leveraging its
molecular diagnostic capabilities to offer nationwide COVID-19
RT-PCR testing to support public health efforts during this
unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220316006140/en/
Investor Contact: LHA
Investor Relations Jody Cain Jcain@lhai.com, 310-691-7100
Media Contact: Sampson PR
Group Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024